Top-News
Professionelle Dienstleistungen Australien

EyePoint Pharmaceuticals News

Aktie
WKN:  A2QJRU ISIN:  US30233G2093 US-Symbol:  EYPT
10,00 €
+0,136 €
+1,38%
30.05.24 17:15:03
Handeln Depot/Watchlist
Aktienanzahl *
34,08 Mio.
Marktkapitalisierung *
336,44 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 08.01.2024

EyePoint Pharmaceuticals News

07.12.23 - PR Newswire
Thinking about buying stock in Realty Income, Eyepoint Pharmaceuticals, Altisource Asset Management, Reviva Pharmaceuticals, or Wave Life Sciences?
Thinking about buying stock in Realty Income, Eyepoint Pharmaceuticals, Altisource Asset Management, Reviva Pharmaceuticals, or Wave Life Sciences? PR Newswire
06.11.23 - wallstreet:online Zentralredaktion
November-Top-Aktien von Mizuho: Coterra, Merck und andere: Mit 300 Prozent Kurspotenzial sticht eine hervor!
Das Research-​Team von Mizuho hat seine neuen Aktientipps für den November preisgegeben.Nach der Kursflaute im Oktober befinden sich die großen Aktienindizes wie der Dow ...
03.05.23 - PR Newswire
Thinking about buying stock in ImmunoGen, Mersana Therapeutics, Unisys, Eyepoint Pharmaceuticals, or BioCryst Pharmaceuticals?
Thinking about buying stock in ImmunoGen, Mersana Therapeutics, Unisys, Eyepoint Pharmaceuticals, or BioCryst Pharmaceuticals? PR Newswire
28.01.23 - PR Newswire
EYEPOINT SHAREHOLDER ACTION REMINDER
EYEPOINT SHAREHOLDER ACTION REMINDER PR Newswire
22.01.23 - PR Newswire
EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options
EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him ...
15.01.23 - PR Newswire
EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options
EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him ...
01.01.23 - PR Newswire
EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options
EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him ...
25.12.22 - PR Newswire
EYEPOINT INVESTOR ALERT
EYEPOINT INVESTOR ALERT PR Newswire
18.12.22 - PR Newswire
EYEPOINT INVESTOR ALERT
EYEPOINT INVESTOR ALERT PR Newswire
01.08.22 - PR Newswire
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD PR Newswire
15.07.22 - PR Newswire
EyePoint Pharmaceuticals Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD
EyePoint Pharmaceuticals Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD PR Newswire
12.02.22 - PR Newswire
EyePoint Pharmaceuticals Announces Updated Positive Interim Safety and Efficacy Data from Ongoing Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD
EyePoint Pharmaceuticals Announces Updated Positive Interim Safety and Efficacy Data from Ongoing Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet ...
17.11.21 - PR Newswire
Thinking about buying stock in Purecycle Technologies, Innoviz Technologies, CNS Pharmaceuticals, Uphealth, or Eyepoint Pharmaceuticals?
Thinking about buying stock in Purecycle Technologies, Innoviz Technologies, CNS Pharmaceuticals, Uphealth, or Eyepoint Pharmaceuticals? PR Newswire
13.11.21 - PR Newswire
EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD
EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD - Interim six-month ...
27.09.19 - The Motley Fool
3 Top-Biotech-Aktien für September
Biotech-​Aktien entwickeln sich in den Sommermonaten nur selten gut, und 2019 war da keine Ausnahme. So ist beispielsweise der iShares Nasdaq Biotechnology ETF seit dem ...
13.12.10 - Aktiencheck
pSivida FDA-Entscheidung zu Iluvien erwartet - Der Aktionär
Nach Einschätzung der Experten vom Anlegermagazin "Der Aktionär" weist die pSivida-​Aktie ein ausgeglichenes Chance/Risiko-​Verhältnis auf. Die US-​Gesundheitsbehörde FDA ...
28.12.09 - Der Aktionär
Psivida: Kurssprung nach Phase-III-Daten

Newssuche

Videos

29.05.24 +24,01%
Technical Trading: DAX Long Chance kurzfristig
DAX Long Typ: Turbo Open End WKN: VD5FWS Hebel: 28 Laufzeit: OpenEnd Einstieg: Market ... Mehr »